Shaji Kumar, MD, Mayo Clinic, Rochester, MN, provides a rundown of the immunotherapies currently available for the treatment of multiple myeloma, the limitations and where research is likely to take the field. Specifically discussed is CAR T-cell therapy and bispecific T-cell engagers (BiTEs) such as AMG 420. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).